Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
Beom-Jun KimZe-Yi ZhengJonathan T LeiMatthew V HoltAnran ChenJianheng PengDiana FandinoPurba SinghHilda KennedyYongchao DouMaría Del Rosario Chica-ParradoEmmanuel BikorimanaDan YeYunguan WangAriella B HankerNada MohamedSusan G HilsenbeckBora LimJaya Ruth AsirvathamArun SreekumarBing ZhangGeorge MilesMeenakshi AnuragMatthew J EllisEric C ChangPublished in: Cancer research communications (2023)
A major challenge for targeting the consequence of tumor suppressor disruption is the accurate assessment of protein functional inactivation. NF1 can repress both RAS and ER signaling, and a ComboMATCH trial is underway to treat the patients with binimetinib and fulvestrant. Herein we report a MS-verified NF1 IHC assay that can determine a threshold for NF1 loss to predict treatment response. These approaches may be used to identify and expand the eligible patient population.
Keyphrases
- estrogen receptor
- signaling pathway
- lps induced
- pi k akt
- nuclear factor
- oxidative stress
- cancer therapy
- clinical trial
- inflammatory response
- multiple sclerosis
- randomized controlled trial
- high resolution
- high throughput
- study protocol
- immune response
- toll like receptor
- cell proliferation
- phase iii
- phase ii
- open label
- combination therapy
- breast cancer cells